CA3077635A1 - Novel t-cell receptor - Google Patents

Novel t-cell receptor Download PDF

Info

Publication number
CA3077635A1
CA3077635A1 CA3077635A CA3077635A CA3077635A1 CA 3077635 A1 CA3077635 A1 CA 3077635A1 CA 3077635 A CA3077635 A CA 3077635A CA 3077635 A CA3077635 A CA 3077635A CA 3077635 A1 CA3077635 A1 CA 3077635A1
Authority
CA
Canada
Prior art keywords
tcr
cell
clone
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3077635A
Other languages
English (en)
French (fr)
Inventor
Andrew Sewell
Garry DOLTON
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Publication of CA3077635A1 publication Critical patent/CA3077635A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3077635A 2017-10-26 2018-10-22 Novel t-cell receptor Pending CA3077635A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1717578.7 2017-10-26
GBGB1717578.7A GB201717578D0 (en) 2017-10-26 2017-10-26 Novel T-cell receptor
GB1806155.6 2018-04-16
GBGB1806155.6A GB201806155D0 (en) 2017-10-26 2018-04-16 Novel t-cell receptor
PCT/GB2018/053045 WO2019081902A1 (en) 2017-10-26 2018-10-22 NEW LYMPHOCYTE RECEPTOR T

Publications (1)

Publication Number Publication Date
CA3077635A1 true CA3077635A1 (en) 2019-05-02

Family

ID=60580240

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3077635A Pending CA3077635A1 (en) 2017-10-26 2018-10-22 Novel t-cell receptor

Country Status (17)

Country Link
US (2) US11725039B2 (cg-RX-API-DMAC7.html)
EP (2) EP3700925B8 (cg-RX-API-DMAC7.html)
JP (1) JP7289311B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200078497A (cg-RX-API-DMAC7.html)
CN (1) CN111278855B (cg-RX-API-DMAC7.html)
AU (2) AU2018356944A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007880A2 (cg-RX-API-DMAC7.html)
CA (1) CA3077635A1 (cg-RX-API-DMAC7.html)
DK (1) DK3700925T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091015A1 (cg-RX-API-DMAC7.html)
ES (1) ES2907819T3 (cg-RX-API-DMAC7.html)
GB (2) GB201717578D0 (cg-RX-API-DMAC7.html)
IL (1) IL274025A (cg-RX-API-DMAC7.html)
MX (1) MX2020004334A (cg-RX-API-DMAC7.html)
PL (1) PL3700925T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202002537WA (cg-RX-API-DMAC7.html)
WO (1) WO2019081902A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
KR20220147583A (ko) * 2020-01-09 2022-11-03 바이오뮤넥스 파마슈티컬스 Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체
EP4090969A1 (en) * 2020-01-16 2022-11-23 Universität Basel Mr1 ligands and pharmaceutical compositions for immunomodulation
WO2021250511A1 (ko) * 2020-06-10 2021-12-16 주식회사 유틸렉스 Mr1에 결합하는 t-세포 수용체 및 이의 용도
WO2022099297A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Multiplexed engineered ipsc and immune effector cells targeting solid tumors
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
WO2022244876A1 (ja) * 2021-05-20 2022-11-24 慶應義塾 抗腫瘍剤
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023002204A1 (en) 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
KR20230088292A (ko) * 2021-12-10 2023-06-19 주식회사 유틸렉스 MR1 제한적 Panck T 세포 및 이의 제조방법
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
EP3572510B1 (en) 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
AU2018231405B2 (en) * 2017-03-07 2024-02-08 Universität Basel MR1 restricted T cell receptors for cancer immunotherapy
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor

Also Published As

Publication number Publication date
PL3700925T3 (pl) 2022-05-02
GB201806155D0 (en) 2018-05-30
US20210147506A1 (en) 2021-05-20
SG11202002537WA (en) 2020-05-28
AU2018356944A1 (en) 2020-04-16
AU2024202735A1 (en) 2024-05-30
JP7289311B2 (ja) 2023-06-09
US20200369742A1 (en) 2020-11-26
CN111278855B (zh) 2024-04-02
IL274025A (en) 2020-06-30
US11725039B2 (en) 2023-08-15
MX2020004334A (es) 2020-08-03
EP4039700A1 (en) 2022-08-10
ES2907819T3 (es) 2022-04-26
EP3700925B1 (en) 2021-12-29
GB201717578D0 (en) 2017-12-13
WO2019081902A1 (en) 2019-05-02
JP2021500406A (ja) 2021-01-07
EP3700925B8 (en) 2022-02-16
EA202091015A1 (ru) 2020-07-17
DK3700925T3 (en) 2022-04-04
BR112020007880A2 (pt) 2020-10-27
KR20200078497A (ko) 2020-07-01
US11078252B2 (en) 2021-08-03
CN111278855A (zh) 2020-06-12
EP3700925A1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
US11078252B2 (en) T-cell receptor
AU2021202223B2 (en) Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
CA3056542A1 (en) Method
CN116731156A (zh) 用于癌症免疫治疗的转染t细胞和t细胞受体
JP2019506154A (ja) 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法
CN111372944A (zh) 新型γδT细胞受体和其配体
US12479903B2 (en) CD5 specific T cell receptor cell or gene therapy
EP4651887A1 (en) T-cell receptors
HK40034405B (en) Novel t-cell receptor
HK40034405A (en) Novel t-cell receptor
EA045252B1 (ru) Новый т-клеточный рецептор
US20250064854A1 (en) Novel t-cell receptor
Theaker Developing peptide vaccines for breast cancer
WO2024222701A1 (zh) 一种t细胞受体及其用途
Wheeler Identifying a novel γδ T-cell stress ligand: Potential for cancer immunotherapy
HK40099489A (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CN119604524A (zh) 用于癌症疗法的工程化t细胞受体构建体
WO2024148185A2 (en) T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*11:01 in lung cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250903

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260422